What Synvisc Treats: Main Uses and Benefits

Synvisc (hylan G-F 20) is a treatment relevant in conditions characterized by periods of heightened symptoms, commonly used across conditions presenting with acute episodes, such as knee osteoarthritis (OA). It is applied across domains where additional symptomatic support is needed. The treatment is commonly used to help with symptoms related to physical discomfort.

The product is relevant in contexts involving heightened systemic burden and often used during phases when symptoms become more noticeable. The treatment is applied in clinical settings that involve acute or unstable symptom patterns. It may assist with managing symptoms that interfere with daily comfort and supports patients during episodes of heightened discomfort.

This therapeutic approach is commonly used to help with symptom clusters that may become intense or disruptive. The treatment is considered relevant in conditions involving inflammatory or irritative processes, and contributes to easing the overall symptom load during symptomatic periods.

Quick Fact: Support for Physical Discomfort

Regulatory References

1. Synvisc Hylan G-F 20 FDA Prescribing Information

Who Can and Cannot Use Synvisc?

The eligibility for Synvisc (hylan G-F 20) is strictly defined by regulatory documents, focusing primarily on the patient's existing allergies and the status of the knee joint at the time of injection.

Absolute Contraindications (Must Not Use)

Classification	Population/Condition
Absolute Contraindication	Known hypersensitivity (allergy) to hyaluronan preparations (Sodium Hyaluronate derivatives).
Local Contraindication	Presence of knee joint infections or skin diseases/infections in the area of the proposed injection site.

Populations with Limited or Conditional Eligibility

Certain groups and pre-existing conditions require specific caution or lack established safety data according to regulatory labeling.

• Pediatric Patients: Safety and effectiveness have not been established in pediatric patients (le 21 years of age).
• Reproductive Status: Safety and effectiveness are not established in pregnant or lactating women.
• Allergy Risk: Caution is required for patients with allergies to avian products (e.g., egg proteins, feathers), as Synvisc is derived from chicken combs.
• Circulation: Caution is required for patients with evidence of lymphatic or venous stasis (circulatory problems) in the leg to be treated.

Interactions with other medicines and products

Synvisc (hylan G-F 20) is an intra-articular injection with minimal systemic exposure; therefore, its officially documented interaction profile is focused on local chemical incompatibility and procedural constraints rather than systemic drug-drug interactions (e.g., CYP enzyme effects).

Documented Product-Related Restrictions

1. Local Chemical Incompatibility

It is strictly prohibited to use disinfectants containing quaternary ammonium salts (such as benzalkonium chloride) for skin preparation prior to the injection. Regulatory labeling warns that hylan G-F 20 can chemically precipitate (clump) upon contact with these substances, which may compromise the product's integrity and intended effect.

2. Local Co-administration Constraints

The safety and effectiveness of co-injecting or the concomitant use of Synvisc with other substances, including local anesthetics or corticosteroids, have not been established in regulatory documents. Therefore, other medications must not be injected into the knee joint during Synvisc therapy. This is a critical constraint, as co-injection may dilute the Synvisc product, potentially affecting its efficacy and safety profile.

3. Systemic Interactions

Official regulatory information does not document any clinically relevant pharmacokinetic interactions involving CYP enzymes, drug transporters, food, alcohol, or herbal products.

Viscosupplementation: Restoring Fluid Biomechanics

This domain focuses on the physical mechanism where the cross-linked Hylan G-F 20 polymer mechanically restores the viscoelasticity of the synovial fluid. This action enhances the fluid’s capacity for lubrication and shock absorption, resulting in a diminished mechanical load and lower shear forces on the articular cartilage.

---

️ Physical Shielding and Nociception Attenuation

The high molecular weight structure creates a physical barrier that coats the cartilage surface and, significantly, the nociceptive nerve endings within the synovium. This shielding helps reduce the afferent nerve input caused by both friction and local irritation, leading to a modulation of peripheral nociceptive signaling within the joint.

---

Cellular Modulation of Catabolism and Inflammation

Beyond its mechanical role, the polymer interacts with cell surface receptors like CD44 on joint-resident cells, triggering signaling that downregulates genes for pro-inflammatory cytokines (e.g., IL-1beta) and catabolic enzymes (e.g., MMPs). This mechanism supports the regulation of the local catabolic pathway and influences the stability of the intra-articular environment.

Official Administration Instructions for Synvisc

Synvisc (hylan G-F 20) is administered by a healthcare professional as an intra-articular injection, meaning the substance is injected directly into the knee joint. Strict adherence to aseptic administration technique is required to minimize the risk of infection. Before the injection, any existing synovial fluid or joint effusion must be removed from the knee.

Administration Detail	Official Requirement
Route	Intra-articular injection (into the knee joint only)
Dose	16 mg (2 mL) per knee
Frequency	Once a week
Total Course	Three injections total

It is essential that disinfectants containing quaternary ammonium salts are not used for skin preparation, as they can cause precipitation of the hyaluronan component. Synvisc is for single-use only, and any remaining product must be discarded immediately after use.

Patients should avoid strenuous activities or prolonged weight-bearing activities, such as jogging or tennis, for approximately 48 hours following the injection. This product is not authorized for use in pediatric patients (those le 21 years of age), as safety and effectiveness have not been established in this age group. Do not inject the product extra-articularly (outside the joint) or intravascularly, and do not inject other medications into the joint concomitantly with this therapy.

Research evidence / Overview of Studies for Synvisc

Evidence for Use in Knee Osteoarthritis

The primary research for Synvisc (hylan G-F 20) was evaluated in trials assessing short-term or episodic symptom patterns related to knee osteoarthritis (OA), a condition marked by functional limitations and periods of heightened symptoms. This evidence base consists of numerous Randomized Controlled Trials (RCTs), where patients were typically compared to those receiving a control injection, such as saline. Additionally, several independent systematic reviews and meta-analyses have examined the collected data from these pivotal trials. Research examined patients with established knee OA, often those whose symptoms continued despite standard initial approaches like physical therapy and basic pain relievers.

Primary Outcomes Measured in Clinical Trials

Researchers explored how symptoms change over time by focusing on specific, measurable patient-reported outcomes. The outcomes related to physical discomfort were most commonly captured using standardized questionnaires, such as the WOMAC Pain Subscale, which records how patients experience pain during activities like walking or climbing stairs. Functional limitations were also monitored, with studies using tools like the WOMAC Function Subscale to record changes in the ability to perform daily tasks.

Long-Term Studies and Follow-Up Data

The typical observation period for the core comparative trials evaluating hylan G-F 20 was short-to-intermediate, with primary data reported up to approximately 26 weeks (six months) post-injection. Research has explored the patterns of response over time, and findings describe that observations related to symptom changes were consistently monitored during these initial short-term periods. However, longer-term outcomes are not fully established through extensive prospective, placebo-controlled research.

Consistency and Uncertainty in the Evidence

Independent scientific reviews have frequently reported mixed findings or heterogeneity (variability) when combining the data in large analyses. The research highlights that the comparison against a placebo injection (saline) can be challenging because the procedure itself was associated with reported changes in the control group. This contributes to a common research limitation where controlled comparative evidence is limited or complicated. Research provides insight into short-term changes, but there is limited information for longer-term outcomes and the degree of reported change varies based on which study or analysis is reviewed, as noted in systematic scientific reviews.

Key Studies & References

1. SYNVISC ONE® HYLAN G-F 20 Prescribing Information
2. SYNVISC® HYLAN G-F 20 Prescribing Information
3. Viscosupplementation for Knee OA: Little Gain, Big Risks (Systematic Review and Meta-analysis)
4. Osteoarthritis: care and management – NICE guideline (NG226)
5. Study Details | NCT00949494 | Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)

Common questions about Synvisc (FAQ)

Q: How long does the pain relief from Synvisc typically last?

A: Studies and official product information indicate that pain relief following a Synvisc treatment may last for up to six months. However, individual results can vary. You should consult with your healthcare provider to discuss what to expect from your treatment.

Q: What are the most common side effects of Synvisc?

A: According to official product information, the most commonly reported side effects occur locally at the knee joint. These are typically temporary, including pain, swelling, heat, redness, and/or fluid buildup (effusion) in or around the injected knee.

Q: Can Synvisc cause swelling in the knee?

A: Yes, official safety data indicates that swelling and fluid buildup in the injected knee are common, transient adverse reactions. If swelling is severe or prolonged, it is recommended to contact your healthcare provider.

Q: Is it normal to have pain at the injection site after Synvisc?

A: Yes, it is common to experience temporary pain at the injection site in the days following the Synvisc shot. Pain in the injected knee is the most frequently reported local adverse event in clinical trials.

Q: What activities should I avoid right after getting a Synvisc shot?

A: Official warnings recommend that patients avoid strenuous activities or prolonged weight-bearing activities for approximately 48 hours following the injection. Activities like jogging, tennis, or heavy lifting should be avoided during this time.

Q: Can Synvisc improve mobility in the knee?

A: Synvisc is a viscosupplement intended to supplement the natural joint fluid, restoring its lubricating and shock-absorbing properties. This action is intended to reduce discomfort, which can support improved joint mobility in patients with knee osteoarthritis.

Q: Does Synvisc contain any animal products?

A: Yes, the main component of Synvisc is hylan G-F 20, which is derived from chicken combs. For this reason, official warnings advise caution for patients with known allergies to avian proteins, feathers, or egg products.

Q: What should I tell my doctor before getting a Synvisc injection?

A: Patients are advised to inform their healthcare provider of any known allergies or medical conditions before receiving the injection. This includes allergies to hyaluronan or avian products, existing joint infections, and circulatory issues in the leg being treated.

Q: Is Synvisc the same as a cortisone shot?

A: No, Synvisc is not a corticosteroid (or cortisone shot). Synvisc is classified as a viscosupplement, which works by physically supplementing the joint fluid. Cortisone shots are anti-inflammatory drugs. The safety and effectiveness of injecting other medications, including steroids, along with Synvisc have not been established.

Q: Is Synvisc a steroid?

A: No, Synvisc is officially classified as a viscosupplementation agent. Its active ingredient is hylan G-F 20, which is a derivative of sodium hyaluronate, a natural substance found in joint fluid. It is not a steroid medication.

Q: How often can you get Synvisc shots?

A: The initial treatment course is administered as a series of three injections, one week apart. Regulatory documents state that the safety and effectiveness of repeat treatment cycles of Synvisc have not been established. Future treatment decisions are determined by the healthcare provider based on the patient's individual circumstances.

Q: What is the difference between Synvisc and Synvisc One?

A: Both products contain the same active ingredient, hylan G-F 20, but differ in the injection schedule. Synvisc is administered as three separate 2 mL injections, one week apart. Synvisc-One is administered as a single 6 mL injection.

Q: Are there any long-term side effects from getting repeated Synvisc treatments?

A: Official regulatory documents do not provide information on long-term safety. The safety and effectiveness of repeat treatment cycles of Synvisc have not been established. Clinical trials primarily tracked effects over short-to-intermediate periods.

Q: Can Synvisc injections be done in a doctor's office?

A: Yes, Synvisc is administered as an intra-articular injection (into the joint space) by a doctor or other qualified healthcare professional. It is typically performed in a clinical setting, such as a doctor's office or clinic.

Q: Will Synvisc show up on a drug test?

A: Synvisc is a local treatment that has minimal systemic exposure. Since it is a local treatment with minimal systemic exposure, it is unlikely to appear on a standard screening test for commonly abused substances.

Q: Why do doctors recommend Synvisc instead of just physical therapy?

A: Synvisc is indicated for the treatment of pain in knee osteoarthritis when patients have not responded adequately to more conservative treatments. These conservative methods include non-pharmacologic therapies like physical therapy and simple over-the-counter pain relievers.

Q: How soon after a Synvisc shot can I return to heavy exercise?

A: Official warnings recommend avoiding strenuous activities for about 48 hours. After this initial period, it is necessary to consult with a healthcare provider for specific guidance on when it is appropriate to resume heavy exercise or high-impact activities.

Q: Can Synvisc interact with supplements like glucosamine or chondroitin?

A: Official product information focuses on local chemical incompatibility, such as with certain disinfectants. Regulatory documents do not report any clinically relevant systemic interactions with food, alcohol, or dietary supplements like glucosamine or chondroitin.

Q: Is Synvisc effective for shoulder or hip pain?

A: No, Synvisc is only indicated for the treatment of pain in osteoarthritis of the knee. The safety and effectiveness of using the product in other joints, such as the shoulder or hip, have not been established in regulatory documents.

Q: Why is my knee still hurting days after the Synvisc injection?

A: Pain in the knee is a common, temporary adverse event following the injection. If pain is pronounced, patients are advised to notify their healthcare provider to rule out rare but more serious reactions like acute inflammation.

Q: Can I use a heating pad or ice on the injection site after the shot?

A: Official regulatory documents do not provide specific instructions on the use of ice or heat for post-injection comfort. Patients should follow the guidance provided by their healthcare provider regarding any comfort measures.

Q: Why do some people need three shots of Synvisc while others only need one?

A: The product is available in two distinct regimens: Synvisc (three 2 mL injections) and Synvisc-One (a single 6 mL injection). The choice between the two regimens is determined by the healthcare provider based on the patient's specific treatment plan.

Q: Is the Synvisc injection painful to receive?

A: The product is administered via an intra-articular injection by a trained healthcare professional. While the procedure itself may cause discomfort, reported adverse events primarily focus on pain, swelling, and other reactions after the injection.

Q: Do I need to fast or prepare in any special way for a Synvisc shot?

A: There are no special patient preparations, such as fasting, required for a Synvisc injection. The preparation involves the healthcare provider following strict aseptic techniques and preparing the knee joint before the shot.

Q: Is Synvisc considered a long-term treatment for arthritis?

A: Clinical trials primarily evaluated the effectiveness over short-to-intermediate periods, up to about six months. The official documents state that the safety and effectiveness of repeat treatment cycles and long-term outcomes have not been established.

Storage Conditions

Synvisc (hylan G-F 20) must be stored under specific environmental conditions as defined by regulatory labeling. The product requires storage at room temperature, specifically below 30°C (86°F), and must be protected from light. It is mandatory that the product do not freeze to maintain its required stability. The sterile solution must be stored in its original container until use.

Stability and Disposal

Synvisc is supplied in a single-use syringe. The contents must be used immediately once the sterile packaging is opened. Regulatory instructions strictly state to not use the syringe if the package has been opened or damaged. Any unused portion must be discarded in accordance with local regulatory requirements for medicinal waste.